



Docket No. CRD5068USNP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Robert Falotico, et al.

Serial No. : 10/796,397

Art Unit: 1615

Filed : March 9, 2004

Examiner: C. A. Azpuru

For : Local Vascular Delivery of Topotecan in
Combination with Rapamycin to Prevent Restenosis
Following Vascular Injury

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

June 13, 2006

(Date of Deposit)

Carl J. Evens

(Name of applicant, assignee, or Registered Representative)

/Carl J. Evens/

(Signature)

June 13, 2006

(Date of Signature)

Box Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a) (2).

☐ There are no listed references which are not in the English language.

☒ The relevance of those listed references which are not in the English language is as follows: An English language translation has been provided for reference No. 23 (DE 10127011). English language abstracts are included for reference numbers 25 and 26 (WO 03/020331 and WO 03/034944).

☒ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CRD5068USNP/CJE. This form is submitted in triplicate.

Respectfully submitted,

/Carl J. Evens/

Carl J. Evens
Reg. No. 33,874
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2518
DATED: June 13, 2006



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CRD5068USNP	Application No. 10/796,397
	Applicant Robert Falotico, et al.	
	Filing Date March 9, 2004	Group 1615
	Confirmation No. 1881	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	1	3,929,992	12/30/75	Seghal et al.	424	122
	2	3,959,078	05/25/76	Guire	530	350
	3	4,350,160	09/21/82	Kolesov et al.	227	179.1
	4	4,366,819	01/04/83	Kaster	606	153
	5	4,368,736	01/18/83	Kaster	606	153
	6	4,624,257	11/25/86	Berggren et al.	606	153
	7	4,722,906	02/02/88	Guire	436	501
	8	4,733,665	03/29/88	Palmaz	606	108
	9	4,739,762	04/26/88	Palmaz	623	1.11
	10	4,776,337	10/11/88	Palmaz	623	1.11
	11	4,917,090	04/17/90	Berggren et al.	606	153
	12	4,917,091	04/17/90	Berggren et al.	606	153
	13	5,229,172	07/20/93	Cahalan et al.	427	536
	14	5,234,447	08/10/93	Kaster et al.	606	153
	15	5,308,641	05/03/94	Cahalan et al.	427	2.1
	16	5,350,800	09/27/94	Verhoeven et al.	525	54.2
	17	5,415,938	05/16/95	Cahalan et al.	428	409
	18	5,837,313	11/17/98	Ding et al.	427	2.21
	19	6,099,562	08/08/00	Ding et al.	623	1.46
	20	6,120,536	09/19/00	Ding et al.	623	1.43
	21	6,153,252	11/28/00	Hossainy et al.	427	2.3
	22	6,425,898	07/30/02	Wilson et al.	606	108

EXAMINER	DATE CONSIDERED
-----------------	------------------------

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CRD5068USNP	Application No. 10/796,397
	Applicant Robert Falotico, et al.	
	Filing Date March 9, 2004	Group 1615
		Confirmation No. 1881

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	23	10127011 A1	12/12/02	DE	X	
	24	02/064127 A1	08/22/02	WO		
	25	03/020331 A1	03/13/03	WO	X abstract	
	26	03/034944 A1	05/01/03	WO	X abstract	
	27	2005/016187 A1	02/24/05	WO		

EXAMINER	DATE CONSIDERED
----------	-----------------

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CRD5068USNP	Application No. 10/796,397
		Applicant Robert Falotico, et al.	
		Filing Date March 9, 2004	Group 1615
		Confirmation No. 1881	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	28	Ajroldi, G. et al., "Fluoroelastomers-dependence of relaxation phenomena on composition," POLYMER, 1989, 30, 2180-2187	
	29	Berk, B. C. et al., "Heparins and Glucocorticoids Inhibit Restenosis," J. Am. Coll. Cardiol., 1991, 17, 111B-117B	
	30	Beutler, E., "Cladribine (2-chlorodeoxyadenosine)," Lancet, 1992 Oct 17, 340(8825), 952-956	
	31	Brehm, B. R. et al., "Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells," J Cardiovasc Pharmacol, Nov. 2000, 36(5 Suppl 1), S401-S403	
	32	Brehm, B. R. et al., "Chronically elevated endothelin-1 concentrations modulate the beta-adrenergic receptor system in vitro and in vivo," J Cardiovasc Pharmacol. Nov. 2000, 36(5 Suppl 1), S157-S159	
	33	Campbell, G. R. and Campbell, J. H., "Phenotypic Modulation of Smooth Muscle Cells in Primary Culture," In: <i>Vascular Smooth Muscle in Culture</i> , Vol. 1, Ch. 4, Boca Raton, FL: CRC, 1987, pp. 39-55	
	34	Campbell, G. R., et al., "Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis," Exp. Mol. Pathol., April 1985, 42(2), 139-162	
	35	Carrera, C. J. et al., "Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy," J. Clin. Invest, 1990 86(5), 1480-1488	
	36	Carson, D. A. et al., "DNA strand breaks, NAD metabolism, and programmed cell death," Exp Cell Res, 1986 Jun, 164(2), 273-281	
	37	Carson, D. A. et al., "Genetic analysis of deoxyadenosine toxicity in dividing human lymphoblasts," Adv Exp Med Biol, 1986, 195 Pt B, 207-211	

EXAMINER	DATE CONSIDERED
-----------------	------------------------

Form PTO-1449 Modified		Docket No. CRD5068USNP	Application No. 10/796,397
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Robert Falotico, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date March 9, 2004	Group 1615
		Confirmation No. 1881	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	38	Carson, D. A. et al., "Lymphocyte dysfunction after DNA damage by toxic oxygen species. A model of immunodeficiency," J Exp Med., 1986 Mar 1; 163(3), 746-751	
	39	Carson, D. A. et al., "Metabolism to methionine and growth stimulation by 5'-methylthioadenosine and 5'-methylthioinosine in mammalian cells," Biochem Biophys Res Commun, 1983 Apr 29, 112(2), 391-397	
	40	Carson, D. A. et al., "Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes," Blood, 1983 Oct, 62(4), 737-743	
	41	Chang, M. W. et al., "Adenovirus-mediated Over-expression of the Cyclin/Cyclin-dependent," J. Clin. Invest., 1995, 96, 2260-2268	
	42	Clowes, A. W. et al., "Kinetics of cellular proliferation after arterial injury. IV. Heparin inhibits rat smooth muscle mitogenesis and migration," Circ. Res., 1986, 58(6), 839-845	
	43	Clowes, A. W. et al., "Kinetics of cellular proliferation after arterial injury. II. Inhibition of smooth muscle growth by heparin," Lab. Invest., 1985, 52(6), 611-616	
	44	Clowes, A. W. et al., "Significance of quiescent smooth muscle migration in the injured rat carotid artery," Circ Res. 1985, 56(1), 139-145	
	45	Clowes, A. W., "Suppression by heparin of smooth muscle cell proliferation in injured arteries," Nature, 1977, 265(5595), 625-626	
	46	Colburn, M. D. et al., "Dose responsive suppression of myointimal hyperplasia by dexamethasone," J. Vasc. Surg., 1992, 15, 510-518	
	47	Currier, J. W. et al., "Colchicine Inhibits Restenosis After Iliac Angioplasty in the Atherosclerotic Rabbit," Supplement To Circulation, 1989, 80(4), Abstract No. 0263	
	48	Deroanne, C. F. et al., "Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling," Oncogene, 2002, 21 (3), 427-436	

EXAMINER	DATE CONSIDERED
-----------------	------------------------

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CRD5068USNP	Application No. 10/796,397
	Applicant Robert Falotico, et al.	
	Filing Date March 9, 2004	Group 1615
	Confirmation No. 1881	

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	49	Edelman, E. R. et al., "Pathobiologic responses to stenting," Am J. Cardiol. 1998, 81(7A), 4E-6E
	50	Farb, A. et al., "Vascular smooth muscle cell cytotoxicity and sustained inhibition of neointimal formation by fibroblast growth factor 2-saporin fusion protein," Circ. Res., 1997, 80, 542-550
	51	Ferns, G. A. A. et al., "Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF," Science, 1991, 253, 1129-1132
	52	Fischman, D. L. et al., "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease," N. Eng. J. Med., 1994 Aug 25, 331(8), 496-501
	53	Franklin, S. M. et al., "Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials," Coron Artery Dis. 1993 Mar, 4(3), 232-242
	54	Fukuyama, J. et al., "Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet," Eur. J. Pharmacol., 1996, 318, 327-332
	55	Guyton, J. R. et al., "Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin," Circ. Res., 1980, 46, 625-634
	56	Hanson, S. R. et al., "Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone," Proc. Natl. Acad. Sci. USA, 1988, 85, 3184-3188
	57	Hansson, G. K. et al., "Interferon- γ Inhibits Arterial Stenosis After Injury," Circ., 1991, 84, 1266-1272
	58	Jacquiau, H. et al., "Cellular Responses to DNA Topoisomerase I Poisons and the TOR Kinase Inhibitor, Rapamycin," European Journal of Cancer, Pergamon Press November 2002, 38, S63, XP004403642

EXAMINER**DATE CONSIDERED**

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CRD5068USNP	Application No. 10/796,397
	Applicant Robert Falotico, et al.	
	Filing Date March 9, 2004	Group 1615
	Confirmation No. 1881	

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	59	Jonasson, J. et al., "Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury," Proc. Natl., Acad. Sci., 1988, 85, 2303-2306
	60	Lang, R. J. et al., "Effects of 2,3-butanedione monoxime on whole-cell Ca ²⁺ channel currents in single cells of the guinea-pig taenia caeci," J Physiol. 1991 Feb, 433, 1-24
	61	Lang, R. J. et al., "Effects of okadaic acid and ATP gamma S on cell length and Ca(2+)-channel currents recorded in single smooth muscle cells of the guinea-pig taenia caeci.," Br. J. Pharmacol., 1991 Oct, 104(2), 331-336
	62	Liu, M. W. et al., "Trapidil in Preventing Restenosis After Balloon Angioplasty in the Atherosclerotic Rabbit," Circ., 1990, 81, 1089-1093
	63	Lundergan, C. F. et al., "Terbinafine inhibits the mitogenic response to platelet-derived growth factor in vitro and neointimal proliferation in vivo," Am. J. Cardiol., 1991, 17(Suppl. B), 132B-136B
	64	Majesky, M. W. et al., "Heparin regulates smooth muscle S phase entry in the injured rat carotid artery," Circ. Res., 1987, 61, 296-300
	65	Mak, K-H. et al., "Clinical trials to prevent restenosis after percutaneous coronary revascularization," Ann N Y Acad Sci., 1997 Apr 15, 811, 255-84; discussion 284-8. Review
	66	Marx, S. O. et al., "Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells," Circ. Res., 1995, 76, 412-417
	67	Mintz, G. S. et al., "Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study," Circulation. 1996 Jul 1, 94(1), 35-43
	68	Mintz, G. S. et al., "Axial plaque redistribution as a mechanism of percutaneous transluminal coronary angioplasty," Am J Cardiol, 1996 Feb 15, 77(5), 427-430
	69	Mintz, G. S. et al., "Intravascular Ultrasound Assessment of the Mechanisms and Predictors of Restenosis Following Coronary Angioplasty," J Invasive Cardiol., 1996 Jan, 8(1), 1-14

EXAMINER	DATE CONSIDERED
-----------------	------------------------

Form PTO-1449 Modified		Docket No. CRD5068USNP	Application No. 10/796,397
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Robert Falotico, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date March 9, 2004	Group 1615
		Confirmation No. 1881	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	70	Mintz, G. S. et al., "Intravascular ultrasound findings after excimer laser coronary angioplasty," Cathet Cardiovasc Diagn. 1996 Feb, 37(2), 113-118	
	71	Mintz, G. S. et al., "Intravascular ultrasound predictors of restenosis after percutaneous transcatheter coronary revascularization," J Am Coll Cardiol, 1996 Jun, 27(7), 1678-87	
	72	Mintz, G. S. et al., "Intravascular ultrasound to discern device-specific effects and mechanisms of restenosis," Am J Cardiol. 1996 Aug 14, 78(3A), 18-22	
	73	Mintz, G. S. et al., "Limitations of angiography in the assessment of plaque distribution in coronary artery disease: a systematic study of target lesion eccentricity in 1446 lesions," Circulation. 1996 Mar 1, 93(5), 924-931	
	74	<u>Modern Fluoropolymers</u> , (J. Scheirs, ed.), John Wiley & Sons, New York, 1997, pp. 77-87	
	75	Nemecsek, G. M. et al., "Terbinafine Inhibits the Mitogenic Response to Platelet-Derived Growth Factor <i>in Vitro</i> and Neoinimal Proliferation <i>in Vivo</i> ," J. Pharmacol. Exp. Thera., 1989, 248, 1167-1174	
	76	Okada, T. et al., "Localized Release of Perivascular Heparin Inhibits Intimal Proliferation after Endothelial Injury without Systemic Anticoagulation," Neurosurgery, 1989, 25, 92-98	
	77	Popma, J. J. et al , "Atherectomy of right coronary ostial stenoses: initial and long-term results, technical features and histologic findings," Am J Cardiol., 1991 Feb 15; 67(5), 431-433	
	78	Popma, J. J. et al., "Adjuncts to thrombolysis for myocardial reperfusion," Ann Intern Med., 1991 Jul 1, 115(1), 34-44	
	79	Popma, J. J. et al., "Clinical trials of restenosis after coronary angioplasty," Circulation, 1991 Sep, 84(3), 1426-1436	

EXAMINER	DATE CONSIDERED
-----------------	------------------------

Form PTO-1449 Modified		Docket No. CRD5068USNP	Application No. 10/796,397
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Robert Falotico, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date March 9, 2004	Group 1615
		Confirmation No. 1881	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	80	Popma, J. J. et al., "Clinical, angiographic and procedural correlates of quantitative coronary dimensions after directional coronary atherectomy," J Am Coll Cardiol., 1991 Nov 1, 18(5), 1183-1189	
	81	Powell, J. S. et al., "Inhibitors of Angiotensin-Converting Enzyme Prevent Myointimal Proliferation After Vascular Injury," Science, 1989, 245, 186-188	
	82	Serruys, P. W. et al., "A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease," N Engl J Med, 1994 Aug 25; 331(8), 489-495	
	83	Serruys, P. W. et al., "Evaluation of ketanserine in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial," Circulation. 1993 Oct; 88(4 Pt 1), 1588-1601	
	84	Serruys, P. W. et al., "Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study," Circulation, 1996 Feb 1; 93(3), 412-422	
	85	Serruys, P. W. et al., "Randomized trials of coronary stenting," J Interv Cardiol, 1994 Aug; 7(4), 331	
	86	Serruys, P. W. et al., "Restenosis revisited: insights provided by quantitative coronary angiography," Am Heart J, 1993 Nov; 126(5), 1243-1267	
	87	Serruys, P. W. et al., "The bailout stent. Is a friend in need always a friend indeed?" Circulation, 1993 Nov; 88(5 Pt 1), 2455-2457	
	88	Seto, S. et al., "Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes," J Clin Invest, 1985 Feb, 75(2), 377-383	
	89	Simons, M. et al., "Antisense c-myc oligonucleotides inhibit intimal arterial smooth muscle cell accumulation <i>in vivo</i> ," Nature, 1992, 359, 67-70	
	90	Snow, A. D. et al., "Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells," Am. J. Pathol., 1990, 137, 313-330	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CRD5068USNP	Application No. 10/796,397
	Applicant Robert Falotico, et al.	
	Filing Date March 9, 2004	Group 1615
	Confirmation No. 1881	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	91	Sollot, S. J. et al., "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation after Angioplasty in the Rat," J. Clin. Invest., 1995, 95, 1869-1876
	92	Tanaka, H. et al., "Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury," Circulation, 1993 Oct; 88(4 Pt 1), 1788-1803
	93	Tardif, et al., "Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group," N Engl J Med. 1997 Aug 7; 337(6), 365-372
	94	Teirstein, P. S. et al., "Catheter-based radiotherapy to inhibit restenosis after coronary stenting," N Engl J Med., 1997 Jun 12; 336(24), 1697-1703
	95	Weinberger, J. et al., "Intracoronary irradiation: dose response for the prevention of restenosis in swine," Int. J. Rad. Onc. Biol. Phys., 1996, 36, 767-775
	96	Woo, S. H. et al., "Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors," J. Med Chem, 2002, 45, 2877-2885
	97	Yokoi, H. et al., "Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial," J Am Coll Cardiol., 1997 Oct; 30(4), 855-862

EXAMINER	DATE CONSIDERED
-----------------	------------------------

<i>Application Number</i>	10/796,397
<i>Filing Date</i>	March 9, 2004
<i>First Named Inventor</i>	Robert Falotico
<i>Group Art Unit</i>	1615
<i>Examiner Name</i>	C.A. Azpuru
<i>Attorney Docket Number</i>	CRD5068USNP